PDUFA Date
REGN: FDA Decision: pasatru
August 19, 2026 · pasatru · approval. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 19, 2026
- Company
- REGENERON PHARMACEUTICALS, INC. (REGN)
- Drug
- pasatru
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
PDUFA Dateapproval
FDA Decision: pasatru
- Drug
- pasatru
- Indication
- 1 INDICATIONS AND USAGE PASATRU is indicated to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). PASATRU is an activin signaling inhibitor indicated to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). ( 1 )
Other upcoming events for REGN
Phase 2 StartPhase 2 Start: A Phase 1/2 Open-Label, Safety and Efficacy Study of Neoadjuvant Fianlimab (Anti-LAG-3 Antibody) in
Phase 1 StartPhase 1 Start: A Master Protocol for a Phase 1b Double-Blind, Randomized Study to Assess the Safety, Tolerability,
Phase 1 StartPhase 1 Start: An Open-Label, Multi-Center Phase I Study to Investigate the Safety and Tolerability of REGN17235 in
Phase 3 ReadoutPhase 3 Topline: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥
Phase 3 ReadoutPhase 3 Topline: A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozel